Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084656 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00084656 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 77 participants.
The verdict
NCT00084656, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells. Combining the vaccines with Montanide ISA-51 may cause a stronger immune response and kill more tumor cells. Giving monoclonal antibody therapy together with vaccine therapy may be an effective treatment for stage III or stage IV melanoma. PURPOSE: This phase II trial is studying how well giving monoclonal antibody therapy together with vaccine therapy works in treating patients with resected stage III or stage IV melanoma.
Interventions
- BIOLOGICAL ipilimumab
- BIOLOGICAL Tyrosinase/gp100/MART-1 Peptides
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2004-05-31 |
| Est. Completion | 2009-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084656
The ClinicalTrials.gov registry entry for NCT00084656 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ipilimumab is the first listed.
NCT00084656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084656 about?
NCT00084656 is a clinical study titled "Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Vaccines may make the body build an immune response to kill tumor cells. Combining the vaccines with Montanide ISA-51 may cause a stronger immune res...
What is the current status of trial NCT00084656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2004-05-31. Estimated completion is 2009-10-31.
What interventions are being tested in trial NCT00084656?
The interventions under investigation include: ipilimumab (BIOLOGICAL), Tyrosinase/gp100/MART-1 Peptides (BIOLOGICAL).
Who is sponsoring clinical trial NCT00084656?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.